Drug Profile
TAb 250
Alternative Names: Oncogene proteins; TAb-250-geloninLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Unknown
- Developer Bayer HealthCare Pharmaceuticals
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 24 Jun 2001 No-Development-Reported for Cancer in USA (Unknown route)